Humacyte (HUMA) announced that the FDA has granted a full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Shareholder Alert for Humacyte, Inc. (NASDAQ:HUMA)
- Humacyte announces publication of results on ATEV
- HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Humacyte’s sdATEV device shows efficacy in artery bypass trial in primates